Former CNET editor Dong Ngo has been involved with technology since 2000, starting with testing gadgets and writing code for CNET Labs' benchmarks. He managed CNET's San Francisco Labs, reviews 3D ...

SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate ...

Cel-Sci is struggling to commercialize its Multikine cancer therapy; it recently closed on a small but expensive financing. The company has completed its initial end of phase 3 meeting with the FDA; ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Almost a quarter century ago today, the Xbox debuted one of its most distinct launch titles — and ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority (SFDA) ...

Tristan Jurkovich began his career as a journalist in 2011. His childhood love of video games and writing fuel his passion for archiving this great medium’s history. He dabbles in every genre, but ...

This new Registration Study targets the population of previously untreated resectable stage 3 and 4 head and neck cancer patients who had no lymph node involvement and low PD-L1 tumor expression.

Crypto lending platform Celsius Network has an approximately $1.2 billion gap in its balance sheet, with most liabilities owed to its users. In addition, the firm has filed for bankruptcy protection, ...

Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows ...

Investigators at Memorial Sloan Kettering Cancer Center (MSK) have published results from a clinical trial that found people with recurrent multiple myeloma may benefit from receiving chimeric antigen ...